An independent resource on ibogaine’s cardiac safety risks.
Ibogaine & electrophysiology
Ibogaine and noribogaine can affect the heart’s electrical recovery cycle. The concern is not abstract: prolonged repolarization can create conditions for dangerous rhythm disturbances, especially when other vulnerabilities are present.
This page is a careful overview of known mechanisms, reported clinical patterns, and the limits of the available evidence. It does not offer treatment recommendations or assurances of safety.
Ibogaine is associated with a specific cardiac concern: interference with electrical signaling that helps the ventricles reset between beats. That signal can be represented on an electrocardiogram as the QT interval. When the interval is prolonged, the risk of unstable rhythms may rise, though an ECG number alone does not determine what will happen in any one person.
The active metabolite noribogaine matters because it may remain present after ibogaine itself has declined. That longer pharmacokinetic tail means the relevant period is not necessarily limited to an initial experience. A broader introduction to the topic is available through Ventriva’s overview of cardiac-safety context, while the practical logic used to interpret individual variables is outlined in how cardiac risk is assessed.
Published accounts include QT prolongation, torsades de pointes, ventricular arrhythmias, conduction abnormalities, and deaths reported in settings where the exact chain of events is often difficult to reconstruct. A useful baseline definition is that long QT syndrome describes delayed ventricular repolarization, whether inherited or acquired. Ibogaine-related risk is generally discussed as acquired QT prolongation with potentially many contributors.
Ventricular repolarization is the electrical recovery phase after the heart’s lower chambers contract. One important current involved in that recovery is IKr, carried through channels encoded by the hERG gene. Laboratory and mechanistic literature has linked ibogaine and noribogaine with hERG/IKr blockade, a pathway shared by many medicines and substances capable of delaying repolarization. The FDA’s discussion of drug-induced QT prolongation and torsades de pointes describes why this kind of delay is treated as a serious safety signal.
On an ECG, the QT interval runs from the beginning of ventricular depolarization to the end of ventricular repolarization. It naturally varies with heart rate: faster rates tend to shorten it and slower rates tend to lengthen it. QTc means a QT interval corrected for rate, but correction is an estimate rather than a direct measurement of risk.
Common corrections include Bazett’s formula, QTc = QT/√RR, and Fridericia’s formula, QTc = QT/∛RR. Bazett can overcorrect at faster heart rates and undercorrect at slower rates; Fridericia is often used because it behaves differently across rates. Neither formula resolves uncertainty from changing heart rate, ECG artifact, broad QRS complexes, or the clinical factors that may influence susceptibility.
That distinction matters in conversations that flatten QTc into a pass-or-fail screen. A measured QTc can be informative, but it is not a stand-alone guarantee. The page on factors that can modify cardiac vulnerability explains why a single number is only one part of a larger picture.
Prolonged repolarization can increase the likelihood of early afterdepolarizations—abnormal electrical impulses that arise during recovery—and may create conditions for torsades de pointes (TdP). TdP is a distinctive, potentially self-terminating or escalating form of polymorphic ventricular tachycardia. It can cause palpitations, fainting, seizure-like activity from reduced blood flow to the brain, or sudden collapse.
Ventricular tachycardia is a fast rhythm originating in the ventricles. Ventricular fibrillation is more disorganized: coordinated pumping is lost and it is immediately life-threatening. The American Heart Association’s overview of ventricular fibrillation as a cardiac arrest rhythm helps clarify why reports of malignant ventricular rhythms are treated with such gravity.
Not every electrical concern centers on QT prolongation. Published case material and safety discussions also describe bradycardia, atrioventricular conduction delay, bundle-branch patterns, or other ECG changes. A conduction block means that an electrical impulse is delayed or interrupted as it travels through part of the heart’s wiring system. Its significance varies with type, severity, symptoms, and surrounding conditions.
Clinical language should not be mistaken for a diagnosis of any particular event from a report alone. Collapsed or deceased individuals may have incomplete ECG records, limited toxicology, uncertain timelines, or more than one plausible explanation. The appropriate conclusion is often conditional: a plausible arrhythmic mechanism may exist, while the precise contribution in a specific case remains unresolved.
Ibogaine is metabolized in part to noribogaine, which remains pharmacologically active. The parent compound and metabolite do not necessarily follow the same time course, and their concentrations can differ widely among individuals. Metabolism can also be affected by genetic variation, liver function, drug interactions, and dose uncertainty.
This matters because a person can move beyond the immediately noticeable effects of ibogaine while a metabolite-associated electrophysiologic concern remains relevant. The available literature does not provide a simple universal clock for when all risk has passed. It instead supports a cautious view of a prolonged and variable window.
Polypharmacy is especially important in interpreting this uncertainty. Other substances may themselves prolong QT, alter heart rate, inhibit metabolic pathways, affect electrolytes, or add effects that are difficult to disentangle. The ibogaine HCl guidance in the UK context is one example of why source-specific discussions should be read alongside—not instead of—clear cardiac-risk information.
Risk questions are also not confined to one stated use case. People may encounter ibogaine in discussions of ibogaine for addiction-related treatment claims, combined ibogaine and 5-MeO-DMT retreat settings, or other uses. Those contexts do not remove the need to consider cardiac hazards, and co-exposures can make historical reports harder to interpret.
Reports of fatalities associated with ibogaine have prompted sustained concern, particularly where cardiac causes were suspected or documented. Reviews and case reports describe patterns that may include prolonged QTc, ventricular arrhythmia, electrolyte disturbance, pre-existing illness, medication or substance co-exposure, and detoxification settings with limited screening or monitoring. The recurrent pattern is not a single uniform mechanism; it is the convergence of plausible cardiac toxicity with incomplete risk control and incomplete records.
Case series can identify signals and patterns, but they cannot supply a population-level probability for every setting or individual. Fatality reports can be affected by reporting bias, postmortem limitations, variable product composition, unknown dose, and missing baseline ECG or laboratory data. Conversely, the absence of a reported event does not prove that a product or setting was safe. Evidence should be read as a warning about known hazards and uncertainty, not as a basis for reassurance.
Some public-facing material places emphasis on outcomes or promises. A page discussing questions around reported ibogaine success rates may be relevant to how people encounter the subject, but outcome language cannot answer a cardiac-safety question. Similarly, pages concerning ibogaine and dementia discussions do not change the need to examine electrophysiologic risk on its own terms.
Where deaths have occurred in unscreened or loosely supervised detox contexts, it is tempting to infer that one missing safeguard explains every outcome. The evidence does not support that level of certainty. What it supports is a careful accounting of multiple potentially interacting risks, including medication histories, electrolyte status, cardiovascular disease, bradycardia, illness, withdrawal, and polypharmacy. A provider’s marketing claim is not evidence; comparisons with claims about ibogaine treatment in Mexico should not substitute for independent appraisal of the cardiac record.
These definitions are intended to clarify the evidence, not to determine whether any individual should use ibogaine or any other substance.
QTc is the QT interval adjusted for heart rate. The correction is needed because the uncorrected QT interval changes as heart rate changes, but the available formulas are imperfect. Bazett and Fridericia corrections can produce different values from the same tracing, especially at faster or slower heart rates.
Noribogaine, an active metabolite, can persist after the parent compound declines. The timing of that persistence varies, and a reduced subjective effect does not establish that cardiac electrophysiologic effects have ended.
No. Reports often involve incomplete information and several potential contributors. The recurring concerns—QT prolongation, co-exposures, illness, electrolyte abnormalities, unscreened settings, and uncertain dosing—matter precisely because they can interact and may not be fully documented.
No. An ECG is a time-limited measurement, and interpretation depends on timing, rate correction, medication and substance history, physiology, and changes that may occur later. It is relevant information, not a categorical assurance of safety.
Ibogaine-related cardiac risk is defined by mechanism, time course, reported events, and unresolved uncertainty. For the wider framing behind this resource, see Ventriva’s purpose and evidence principles.